眼科

• 论著 • 上一篇    下一篇

湿性年龄相关性黄斑变性玻璃体注射雷珠单抗治疗一年后视力的影响因素

闫淑  邵玲  杜敏  沈策英  李琰  刘钰  晁阳阳  杨凯转   

  1. 450006 郑州市第二人民医院眼科
  • 收稿日期:2018-05-17 出版日期:2019-11-25 发布日期:2019-12-06
  • 通讯作者: 闫淑,Email:yanshu8302@126.com E-mail:yanshu8302@126.com

Effective factors of one-year visual outcomes after intravitreal injection of ranibizumb for wet age-related macular degeneration

YAN Shu, SHAO Ling, DU Min, SHEN Ce-ying, LI Yan, LIU Yu, CHAO Yang-yang, YANG Kai-zhuan   

  1. Department of  Ophthalmology, Zhengzhou Second People Hospital, Zhengzhou 450006, China
  • Received:2018-05-17 Online:2019-11-25 Published:2019-12-06
  • Contact: YAN Shu, Email: yanshu8302@126.com E-mail:yanshu8302@126.com

摘要:

目的 观察湿性年龄相关性黄斑变性(wAMD)玻璃体注射雷珠单抗治疗1年后视力及其影响因素。设计 回顾性病例系列。研究对象 郑州市第二人民医院眼科2015年5月至2017年2月wAMD患者50例(50眼)。方法  所有患者均接受最佳矫正视力(BCVA)、眼底彩色照相、荧光素眼底血管造影(FFA)、相干光断层扫描(OCT)及相干光断层扫描血管成像(OCT-A)检查。所有患眼均采用每月注射 1 次连续注射 3 个月后按需治疗的方案行玻璃体注射雷珠单抗治疗。观察治疗1年后的BCVA。分析治疗1年后的终末BCVA及提高程度与基线特征年龄、性别、基线BCVA、黄斑下视网膜出血、视网膜内液、视网膜下液、视网膜色素上皮脱离、黄斑中心凹视网膜厚度(CFT)、脉络膜新生血管(CNV)面积及CNV的类型(经典为主型、微小经典型、隐匿型)的相关性。主要指标  BCVA、黄斑下视网膜出血、视网膜内液、视网膜下液、视网膜色素上皮脱离、CFT、CNV的面积,CNV的类型。结果 治疗前BCVA为(53.4±14.5)个字母,治疗1年后BCVA为(61.3±20.5)个字母,提高(7.9±8.5)个字母(t=-6.564,P<0.01)。治疗1年后的终末BCVA与基线BCVA正相关(B=0.483,P=0.001),与治疗前CNV面积和CNV的类型负相关(B=-0.211,P=0.005;B=-0.202, P=0.005);治疗1年后BCVA的提高程度与治疗前CNV面积和CNV类型负相关(B =-0.509,P=0.005;B=-0.488, P=0.005)。三种类型的CNV中,经典为主型CNV治疗1年后的BCVA较差,隐匿型的终末BCVA较好,经典为主型BCVA提高程度较少,微小经典型提高程度较大(P<0.05)。结论 经典为主型CNV、CNV面积大者,玻璃体注射雷珠单抗1年后视力改善较小、预后差;基线视力较好者会有较好的终末视力。

关键词: 湿性年龄相关性黄斑变性, 雷珠单抗, 视力

Abstract:

Objective To investigate one-year visual outcomes after intravitreal injection of ranibizumb for wet age-related macular degeneration(wAMD) and its influencing factors. Design Retrospective case series. Participants  Fifty cases (50 eyes) of  wAMD  in Zhengzhou Second People Hospital form May 2015 to February 2017. Methods All subjects received  eye examination, including best corrected visual acuity (BCVA), funds color photography, fundus fluorescein angiography (FFA), optical coherence tomography (OCT) and OCT angiography(OCT-A). The scheme of intravitreal injection ranibizumb consisted of once a month for three month, followed by an PRN scheme. The one year BCVA  and the change of BCVA  from pretherapy to  post-treatment were observed. The correlation between the one year BCVA , improvement and baseline factors that include age, gender, baseline BCVA, macular subretinal hemorrhage, intraretinal fluid, subretina fluid, pigment epithelium detachment, central foveal thickness (CFT), area of  choroidal neovascularization (CNV),  type of CNV (predominantly classic, min classic and  latent ) were analyzed. Main Outcome Measures BCVA, macular subretinal hemorrhage, intraretinal fluid, subretina fluid, pigment epithelium detachment, CFT, area of CNV and the type of  CNV.  Results Before therapy , BCVA was (53.4±14.5) letters, and 1 year after therapy, BCVA was (61.3±20.5) letters, improvement letters was  (7.9±8.5) (t=-6.564, P<0.01). Multiple linear regression shows that baseline BCVA was opsitive associated with  BCVA outcomes at 1 year (B=0.483, P=0.001); area of  CNV  and type of CNV was  negative associated with  BCVA outcomes at 1 year ( B=-0.211, P=0.005; B=-0.202, P=0.005). That area of  CNV and type of CNV was negative associated with improved BCVA score at 1 year  (B=-0.509, P=0.005; B=-0.488, P=0.005). BCVA outcomes of 1 year of predominantly classic CNV was worst and latent was best, the improved BCVA at 1 year of predominantly classic CNV was least and  min classic CNV was most (P<0.05). Conclusion Predominantly classic CNV and  bigger area of CNV have little improvement of one-year BCVA and poor prognosis. People who with better baseline BCVA will have better BCVA at one year.

Key words: wet age-related macular degeneration, ranibizumb, visual acuity